Keros Therapeutics, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Keros Therapeutics, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $243.86M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $0 | Mar 4, 2026 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $244.06M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $3.55M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $151.0K | Feb 26, 2025 |
| FY2024 | Dec 31, 2022 | $0 | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $20.10M | Feb 28, 2024 |
| FY2021 | Dec 31, 2020 | $0 | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | $10.00M | Mar 25, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $87.01M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | ($187.35M) | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | ($152.99M) | Feb 26, 2025 |
| FY2024 | Dec 31, 2022 | ($104.68M) | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | ($58.74M) | Feb 28, 2024 |
| FY2021 | Dec 31, 2020 | ($45.36M) | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | ($12.34M) | Mar 25, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $67.57M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | ($210.83M) | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | ($169.94M) | Feb 26, 2025 |
| FY2024 | Dec 31, 2022 | ($114.79M) | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | ($56.37M) | Feb 28, 2024 |
| FY2021 | Dec 31, 2020 | ($46.66M) | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | ($10.56M) | Mar 25, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $129.64M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $173.63M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $135.26M | Feb 26, 2025 |
| FY2024 | Dec 31, 2022 | $87.27M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $55.14M | Feb 28, 2024 |
| FY2021 | Dec 31, 2020 | $33.86M | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | $17.38M | Mar 25, 2021 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $107.51M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | ($160.87M) | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | ($124.51M) | Feb 26, 2025 |
| FY2024 | Dec 31, 2022 | ($70.06M) | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | ($62.15M) | Feb 28, 2024 |
| FY2021 | Dec 31, 2020 | ($36.89M) | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | ($16.00M) | Mar 25, 2021 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.55M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $1.93M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $2.46M | Feb 26, 2025 |
| FY2024 | Dec 31, 2022 | $1.24M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $1.02M | Feb 28, 2024 |
| FY2021 | Dec 31, 2020 | $294.0K | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | $271.0K | Mar 25, 2021 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $338.02M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $615.89M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $370.03M | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $306.78M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $255.25M | Mar 3, 2023 |
| FY2021 | Dec 31, 2020 | $269.44M | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | $10.96M | Mar 25, 2021 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $34.89M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $44.33M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $37.81M | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $29.36M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $12.08M | Mar 3, 2023 |
| FY2021 | Dec 31, 2020 | $7.72M | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | $10.46M | Mar 25, 2021 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $303.13M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $571.55M | Mar 4, 2026 |
| FY2025 | Dec 31, 2023 | $332.21M | Mar 4, 2026 |
| FY2024 | Dec 31, 2022 | $277.42M | Feb 26, 2025 |
| FY2024 | Dec 31, 2021 | $243.17M | Feb 26, 2025 |
| FY2023 | Dec 31, 2020 | $261.72M | Feb 28, 2024 |
| FY2021 | Dec 31, 2019 | ($19.45M) | Mar 9, 2022 |
| FY2020 | Dec 31, 2018 | ($7.18M) | Mar 25, 2021 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($481.77M) | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | ($568.78M) | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | ($381.43M) | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | ($228.43M) | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | ($123.76M) | Mar 3, 2023 |
| FY2021 | Dec 31, 2020 | ($65.01M) | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | ($19.65M) | Mar 25, 2021 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $287.42M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $559.93M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $331.15M | Feb 26, 2025 |
| FY2024 | Dec 31, 2022 | $279.05M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $230.04M | Feb 28, 2024 |
| FY2021 | Dec 31, 2020 | $265.88M | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | $7.02M | Mar 25, 2021 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2 | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | (5) | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | (5) | Feb 26, 2025 |
| FY2024 | Dec 31, 2022 | (4) | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | (2) | Feb 28, 2024 |
| FY2021 | Dec 31, 2020 | (2) | Mar 9, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2 | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | (5) | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | (5) | Feb 26, 2025 |
| FY2024 | Dec 31, 2022 | (4) | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | (2) | Feb 28, 2024 |
| FY2021 | Dec 31, 2020 | (2) | Mar 9, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 19.54M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | 40.55M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | 31.84M | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | 27.54M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | 23.97M | Mar 3, 2023 |
| FY2021 | Dec 31, 2020 | 23.19M | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | 2.43M | Mar 25, 2021 |